Carmel, IN – According to filings with the U.S. Securities and Exchange Commission, MBX Biosciences is raising $115,184,430.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Kent Hawryluk played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About MBX Biosciences
MBX Biosciences, Inc. is a clinical stage biopharmaceutical company pioneering investigational Precision Endocrine Peptides (PEPs). PEPs are designed to overcome key limitations of native peptide therapeutics to deliver superior pharmacologic properties. MBX is advancing a pipeline of PEP candidates to address the unmet needs of people with endocrine disorders. The company’s lead product candidate, MBX 2109 for the treatment of hypoparathyroidism, is currently in a Phase 1 clinical trial. Members of MBXs leadership team have collaborated over several decades on the discovery, development, and commercialization of highly successful endocrine therapeutics including Forteo and Humalog. The company is supported by leading life science investors including Frazier Life Sciences, New Enterprise Associates and OrbiMed.

To learn more about MBX Biosciences, visit http://www.mbxbio.com/

Contact:
Kent Hawryluk, Chief Executive Officer
317-659-0200
https://www.linkedin.com/in/khawryluk/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved